Loading...
•
Dec 31, 2025
PTC Therapeutics Q4 2025 Earnings Report
PTC Therapeutics reported fourth quarter 2025 results with lower total revenues year-over-year and a higher net loss driven by operating expenses and a Translarna France adjustment.
Key Takeaways
For Q4 2025, PTC Therapeutics generated total revenues of 164677000 dollars, reflecting lower collaboration revenue and a significant Translarna France adjustment. The company reported a net loss of 134965000 dollars and a loss from operations of 71349000 dollars, while maintaining a strong cash position of 1945371000 dollars at year end.
Total revenues were 164677000 dollars in Q4 2025.
Net loss was 134965000 dollars with operating loss of 71349000 dollars.
GAAP R&D expenses increased to 133128000 dollars.
Cash, cash equivalents and marketable securities totaled 1945371000 dollars at quarter end.
Revenue by Segment
Forward Guidance
For full year 2026, PTC expects total product revenue of 700000000 to 800000000 dollars and GAAP R&D and SG&A expenses of 775000000 to 815000000 dollars.
Positive Outlook
- 2026 product revenue expected between 700000000 and 800000000 dollars.
- Majority of 2026 revenue growth expected from Sephience.
- Strong cash balance supports operations.
- Non-GAAP expense guidance excludes significant non-cash stock compensation.
- Global expansion of Sephience footprint expected.
Challenges Ahead
- Projected GAAP R&D and SG&A expenses between 775000000 and 815000000 dollars.
- Continued operating losses in Q4 2025.
- Decline in Translarna revenue year-over-year.
- Decline in Emflaza revenue year-over-year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...